Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 219

1.

Hemodynamic stability after transitioning between endothelin receptor antagonists in patients with pulmonary arterial hypertension.

Fox B, Langleben D, Hirsch AM, Schlesinger RD, Eisenberg MJ, Joyal D, Blenkhorn F, Lesenko L.

Can J Cardiol. 2013 Jun;29(6):672-7. doi: 10.1016/j.cjca.2012.05.013. Epub 2012 Jul 21.

PMID:
22819360
2.

Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.

Dranitsaris G, Mehta S.

Appl Health Econ Health Policy. 2009;7(1):43-59. doi: 10.2165/00148365-200907010-00005.

PMID:
19558194
3.

Transitioning between endothelin receptor blockers: monitoring to ensure a smooth transition.

Luo N, Ryan JJ.

Can J Cardiol. 2013 Jun;29(6):659-61. doi: 10.1016/j.cjca.2012.07.006. Epub 2012 Sep 15. No abstract available.

PMID:
22985784
4.

Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities.

McGoon MD, Frost AE, Oudiz RJ, Badesch DB, Galie N, Olschewski H, McLaughlin VV, Gerber MJ, Dufton C, Despain DJ, Rubin LJ.

Chest. 2009 Jan;135(1):122-129. doi: 10.1378/chest.08-1028. Epub 2008 Sep 23.

PMID:
18812445
5.
6.

Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension.

Steiner MK, Preston IR.

Vasc Health Risk Manag. 2008;4(5):943-52. Review.

7.

Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension.

Safdar Z.

Vasc Health Risk Manag. 2011;7:119-24. doi: 10.2147/VHRM.S15026. Epub 2011 Mar 2.

8.

Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases.

Humbert M, Simonneau G.

Nat Clin Pract Rheumatol. 2005 Dec;1(2):93-101. Review.

PMID:
16932638
9.

Endothelin receptor antagonists for the treatment of pulmonary artery hypertension.

Rubin LJ.

Life Sci. 2012 Oct 15;91(13-14):517-21. doi: 10.1016/j.lfs.2012.07.033. Epub 2012 Aug 3. Review.

10.

Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension.

Gabler NB, French B, Strom BL, Liu Z, Palevsky HI, Taichman DB, Kawut SM, Halpern SD.

Chest. 2012 Jan;141(1):20-26. doi: 10.1378/chest.11-0404. Epub 2011 Sep 22.

PMID:
21940766
11.

A review of pulmonary arterial hypertension: role of ambrisentan.

Barst RJ.

Vasc Health Risk Manag. 2007;3(1):11-22. Review.

12.

Safety and efficacy evaluation of ambrisentan in pulmonary hypertension.

Vizza CD, Fedele F, Pezzuto B, Rubin LJ.

Expert Opin Drug Saf. 2012 Nov;11(6):1003-11. doi: 10.1517/14740338.2012.714770. Epub 2012 Aug 4.

PMID:
22861496
13.

Endothelin receptor antagonists as disease modifiers in systemic sclerosis.

Shetty N, Derk CT.

Inflamm Allergy Drug Targets. 2011 Feb;10(1):19-26. Review.

PMID:
21184655
14.

Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan.

Benza RL, Mehta S, Keogh A, Lawrence EC, Oudiz RJ, Barst RJ.

J Heart Lung Transplant. 2007 Jan;26(1):63-9.

PMID:
17234519
15.

[Treatment of pulmonary arterial hypertension: endothelin-receptor antagonists].

Hoeper MM.

Dtsch Med Wochenschr. 2006 Dec 8;131(49 Suppl 9):S308-10. Review. German.

PMID:
17139593
16.

Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension.

Klinger JR, Oudiz RJ, Spence R, Despain D, Dufton C.

Am J Cardiol. 2011 Jul 15;108(2):302-7. doi: 10.1016/j.amjcard.2011.03.037. Epub 2011 May 3.

PMID:
21545989
17.

Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?

Opitz CF, Ewert R, Kirch W, Pittrow D.

Eur Heart J. 2008 Aug;29(16):1936-48. doi: 10.1093/eurheartj/ehn234. Epub 2008 Jun 17. Review.

18.

Role of ambrisentan in the management of pulmonary hypertension.

Hrometz SL, Shields KM.

Ann Pharmacother. 2008 Nov;42(11):1653-9. doi: 10.1345/aph.1L014. Epub 2008 Oct 28. Review. Erratum in: Ann Pharmacother. 2009 Apr;43(4):794. Dosage error in article text.

PMID:
18957622
19.

Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension.

Takatsuki S, Rosenzweig EB, Zuckerman W, Brady D, Calderbank M, Ivy DD.

Pediatr Pulmonol. 2013 Jan;48(1):27-34. doi: 10.1002/ppul.22555. Epub 2012 Apr 17.

20.

Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan.

Barst RJ, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S, Naeije R, Galie N; STRIDE-2 Study Group.

J Am Coll Cardiol. 2006 May 16;47(10):2049-56. Epub 2006 Apr 24.

Supplemental Content

Support Center